Rosuvastatin, a statin, effectively lowers LDL cholesterol by inhibiting HMG-CoA reductase. PCSK9 inhibitors, like alirocumab, enhance LDL receptor recycling, further reducing LDL. Statins are oral, cost-effective, and widely used, but may cause muscle pain. PCSK9 inhibitors, administered via injection, are more potent but significantly more expensive and primarily used when statins are insufficient or unsuitable.